All In Biotech

Drug Trial Radar · NCT03759665

N-Acetyl-L-Leucine for GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease)

Effects of N-Acetyl-L-Leucine on GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease): A Multinational, Multicenter, Open-label, Rater-blinded Phase II Study

Last checked: Nov 20, 2026Latest source record: Mar 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

30

Actual

Start

Jun 7, 2019

Primary completion

Jan 9, 2023

Study completion Jan 9, 2023

Sponsor

Lead sponsor
IntraBio IncIndustry
Sponsor type
Industry
First posted
Nov 30, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multinational, multicenter, open-label, rater-blinded prospective Phase II study which will assess the safety and efficacy of N-Acetyl-L-Leucine (IB1001) for the treatment of GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease). There are two phases to this study: the Parent Study, and the Extension Phase. The Parent Study evaluates the safety and efficacy of N-Acetyl-L-Leucine (IB1001) in the symptomatic treatment of GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease). The Extension Phase evaluates the long-term safety and efficacy of IB1001 for the neuroprotective, disease-modifying treatment of GM2 Gangliosidosis. The Extension Phase was considered exploratory.

Conditions

  • GM2 Gangliosidosis
  • Tay-Sachs Disease
  • Sandhoff Disease

Interventions

  • IB1001Drug

    IB1001 (N-Acetyl-L-Leucine) is a modified amino-acid ester that is orally administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical Impression of Change in Severity (CI-CS) [Fields et al 2021]Time frame: (CI-CS comparing Baseline [Day 1] with IB1001 versus the end of 6-weeks treatment with IB1001 [approximately Day 42]) MINUS (CI-CS comparing the end of 6-weeks treatment with IB1001 [approximately Day 42] versus end of 6-weeks post-treatment washout);

Locations

8 sites in 4 countries. Site status is shown where the registry gives one.

  • University of California - Los Angeles

    Los Angeles, California

  • Mayo Clinic

    Rochester, Minnesota

  • NYU Langone School of Medicine

    New York, New York

  • University of Giessen

    Giessen, Germany

  • Ludwig Maximilian University of Munich

    München, Germany

  • Bellvitge University Hospital

    Barcelona, Spain

  • Royal Manchester Children's Hospital

    Manchester, United Kingdom

  • Salford Trust

    Salford, Greater Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.